Clinical Trial Update: Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update evaluating a combination of Anastrozole, Palbociclib, Trastuzumab, and Pertuzumab in HR-positive, HER2-positive metastatic bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• HERCEPTIN (trastuzumab)
• IBRANCE (PALBOCICLIB)
• Perjeta (pertuzumab)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Breast Neoplasms, Breast Diseases | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING